Cartesian Therapeutics (RNAC) Amortizatization of Intangibles (2016 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Amortizatization of Intangibles of $235000.0 for Q1 2026, up 27.72% year-over-year from $184000.0 in Q1 2025, and up 9.3% quarter-over-quarter from $215000.0 in Q4 2025.
Powered by 
Analysis
Cartesian Therapeutics (RNAC) Amortizatization of Intangibles (2016 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Amortizatization of Intangibles for 11 consecutive years, with $235000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortizatization of Intangibles rose 27.72% year-over-year to $235000.0; the TTM figure through Mar 2026 stood at $829000.0 (down 60.69% YoY), while the FY2025 annual figure was $778000.0, down 68.08% from the prior year.
- Amortizatization of Intangibles improved to $235000.0 in Q1 2026 per RNAC's latest filing, from $215000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $1.2 million in Q4 2022 and bottomed at -$1.2 million in Q4 2023.
- Historically, Amortizatization of Intangibles has averaged $286235.3 across 5 years, with a median of $235000.0 in 2026.
- Annual changes were most pronounced in 2022 — Amortizatization of Intangibles slumped 5044.44% — and 2023, when it jumped 41700.0%.
- Cartesian Therapeutics' Amortizatization of Intangibles stood at $1.2 million in 2022, then plunged by 199.17% to -$1.2 million in 2023, then jumped by 155.96% to $671000.0 in 2024, then plunged by 67.96% to $215000.0 in 2025, then gained by 9.3% to $235000.0 in 2026.
- Business Quant data shows RNAC's Amortizatization of Intangibles at $235000.0 in Q1 2026, $215000.0 in Q4 2025, and $192000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Cartesian Therapeutics | 271.98 Mn | 271.98 Mn | - | 242,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 242,000.00 |
| Mar 31, 2026 | 235,000.00 |
| Dec 31, 2025 | 215,000.00 |
| Sep 30, 2025 | 192,000.00 |
| Jun 30, 2025 | 187,000.00 |
| Mar 31, 2025 | 184,000.00 |
| Dec 31, 2024 | 671,000.00 |
| Sep 30, 2024 | 653,000.00 |
| Jun 30, 2024 | 601,000.00 |
| Mar 31, 2024 | 512,000.00 |
| Dec 31, 2023 | 476,000.00 |
| Sep 30, 2023 | 436,000.00 |
| Jun 30, 2023 | 426,000.00 |
| Mar 31, 2023 | 416,000.00 |
| Dec 31, 2022 | 407,000.00 |
| Sep 30, 2022 | 339,000.00 |
| Jun 30, 2022 | 298,000.00 |
| Mar 31, 2022 | 293,000.00 |
| Dec 31, 2021 | 287,000.00 |
| Sep 30, 2021 | 283,000.00 |